EBV-associated Diseases: Current Therapeutics and Emerging Technologies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 17

PMID 36389670

Authors

Srishti Chakravorty

Behdad Afzali

Majid Kazemian

Affiliations

Soon will be listed here.

Abstract

EBV is a prevalent virus, infecting >90% of the world's population. This is an oncogenic virus that causes ~200,000 cancer-related deaths annually. It is, in addition, a significant contributor to the burden of autoimmune diseases. Thus, EBV represents a significant public health burden. Upon infection, EBV remains dormant in host cells for long periods of time. However, the presence or episodic reactivation of the virus increases the risk of transforming healthy cells to malignant cells that routinely escape host immune surveillance or of producing pathogenic autoantibodies. Cancers caused by EBV display distinct molecular behaviors compared to those of the same tissue type that are not caused by EBV, presenting opportunities for targeted treatments. Despite some encouraging results from exploration of vaccines, antiviral agents and immune- and cell-based treatments, the efficacy and safety of most therapeutics remain unclear. Here, we provide an up-to-date review focusing on underlying immune and environmental mechanisms, current therapeutics and vaccines, animal models and emerging technologies to study EBV-associated diseases that may help provide insights for the development of novel effective treatments.

Citing Articles

Metformin in Antiviral Therapy: Evidence and Perspectives.

Halabitska I, Petakh P, Lushchak O, Kamyshna I, Oksenych V, Kamyshnyi O Viruses. 2025; 16(12.

PMID: 39772244 PMC: 11680154. DOI: 10.3390/v16121938.

The interplay of EBV virus and cell metabolism in lung cancer.

Wang H J Cell Mol Med. 2024; 28(22):e70088.

PMID: 39601114 PMC: 11599874. DOI: 10.1111/jcmm.70088.

Research landmarks on the 60th anniversary of Epstein-Barr virus.

Zhong L, Xie C, Zhang L, Yang Y, Liu Y, Zhao G Sci China Life Sci. 2024; 68(2):354-380.

PMID: 39505801 DOI: 10.1007/s11427-024-2766-0.

EBV-Positive Classic Hodgkin Lymphoma and Primary Nodal T-Cell/NK-Cell Lymphoma Arising in the Background of Follicular Lymphoma.

Raychaudhuri S, Dong Z, Knowles S, Graf S Case Rep Hematol. 2024; 2024:8810646.

PMID: 39290203 PMC: 11407883. DOI: 10.1155/2024/8810646.

The Impact of Oral Microbiome Dysbiosis on the Aetiology, Pathogenesis, and Development of Oral Cancer.

Talapko J, Eric S, Mestrovic T, Stipetic M, Juzbasic M, Katalinic D Cancers (Basel). 2024; 16(17).

PMID: 39272855 PMC: 11394246. DOI: 10.3390/cancers16172997.

References

Green M, Rodig S, Juszczynski P, Ouyang J, Sinha P, ODonnell E . Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18(6):1611-8. PMC: 3321508. DOI: 10.1158/1078-0432.CCR-11-1942. View

Louis C, Straathof K, Bollard C, Ennamuri S, Gerken C, Lopez T . Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010; 33(9):983-90. PMC: 2964409. DOI: 10.1097/CJI.0b013e3181f3cbf4. View

Cohen J . Vaccine Development for Epstein-Barr Virus. Adv Exp Med Biol. 2018; 1045:477-493. PMC: 6328312. DOI: 10.1007/978-981-10-7230-7_22. View

Kintner C, Sugden B . The structure of the termini of the DNA of Epstein-Barr virus. Cell. 1979; 17(3):661-71. DOI: 10.1016/0092-8674(79)90273-3. View

Gallo A, Miele M, Badami E, Conaldi P . Molecular and cellular interplay in virus-induced tumors in solid organ recipients. Cell Immunol. 2018; 343:103770. DOI: 10.1016/j.cellimm.2018.02.010. View

Lau R, Middeldorp J, Farrell P . Epstein-Barr virus gene expression in oral hairy leukoplakia. Virology. 1993; 195(2):463-74. DOI: 10.1006/viro.1993.1397. View

ABELE G, Eriksson B, Harmenberg J, Wahren B . Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob Agents Chemother. 1988; 32(8):1137-42. PMC: 172365. DOI: 10.1128/AAC.32.8.1137. View

Hurley E, Thorley-Lawson D . B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med. 1988; 168(6):2059-75. PMC: 2189139. DOI: 10.1084/jem.168.6.2059. View

Chang Y, Tyan Y, Liu S, Tsai M, PAO C . Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol. 1990; 28(11):2398-402. PMC: 268195. DOI: 10.1128/jcm.28.11.2398-2402.1990. View

10.

Gallant J, Daar E, Raffi F, Brinson C, Ruane P, DeJesus E . Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind,.... Lancet HIV. 2016; 3(4):e158-65. DOI: 10.1016/S2352-3018(16)00024-2. View

11.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P . Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14):1428-1439. PMC: 6075855. DOI: 10.1200/JCO.2017.76.0793. View

12.

Takizawa M, Tolarova H, Li Z, Dubois W, Lim S, Callen E . AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med. 2008; 205(9):1949-57. PMC: 2526190. DOI: 10.1084/jem.20081007. View

13.

Wood C, Veenstra H, Khasnis S, Gunnell A, Webb H, Shannon-Lowe C . MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. Elife. 2016; 5. PMC: 5005034. DOI: 10.7554/eLife.18270. View

14.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

15.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

16.

Alfieri C, Birkenbach M, Kieff E . Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 1991; 181(2):595-608. DOI: 10.1016/0042-6822(91)90893-g. View

17.

Li D, Fu W, Swaminathan S . Continuous DNA replication is required for late gene transcription and maintenance of replication compartments in gammaherpesviruses. PLoS Pathog. 2018; 14(5):e1007070. PMC: 5993329. DOI: 10.1371/journal.ppat.1007070. View

18.

Sun K, Jia K, Lv H, Wang S, Wu Y, Lei H . EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives. Front Oncol. 2020; 10:583463. PMC: 7769310. DOI: 10.3389/fonc.2020.583463. View

19.

Rahman N, Sun J, Li Z, Pattnaik A, Mohallem R, Wang M . The cytoplasmic LSm1-7 and nuclear LSm2-8 complexes exert opposite effects on Hepatitis B virus biosynthesis and interferon responses. Front Immunol. 2022; 13:970130. PMC: 9396650. DOI: 10.3389/fimmu.2022.970130. View

20.

Guikema J, Schuuring E, Kluin P . Structure and consequences of IGH switch breakpoints in Burkitt lymphoma. J Natl Cancer Inst Monogr. 2008; (39):32-6. DOI: 10.1093/jncimonographs/lgn020. View